Related Experiment Video
Updated: Jun 7, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
19.8K
Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the
Denis Mongin1, Marco Matucci-Cerinic2, Ulrich A Walker3
1Geneva University Hospitals, Geneva, Switzerland.
Arthritis Care & Research
|November 14, 2024
Summary
Adding low-dose oral glucocorticoids to immunosuppression did not improve skin scores in early diffuse cutaneous systemic sclerosis (dcSSc). This treatment also did not increase the risk of scleroderma renal crisis, showing no significant benefit for skin fibrosis.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Systemic sclerosis is a chronic autoimmune disease characterized by fibrosis.
- Diffuse cutaneous systemic sclerosis (dcSSc) involves widespread skin thickening and internal organ involvement.
- Optimal treatment for early dcSSc remains under investigation, balancing efficacy and safety.
Purpose of the Study:
- To determine if adding oral glucocorticoids to immunosuppressive therapy improves skin scores in early dcSSc.
- To assess the safety of combined therapy, specifically the risk of scleroderma renal crisis.
Main Methods:
- An emulated randomized trial design was used, comparing patients with early dcSSc on immunosuppression with or without low-dose oral glucocorticoids (prednisone equivalent ≤20 mg/day).
- The primary outcome was the change in modified Rodnan skin score (mRSS) at 12 ± 3 months.
- Propensity score matching was employed to control for baseline differences between the treated and control groups.
Main Results:
- A total of 208 patients were matched (104 per group), with comparable baseline characteristics.
- No significant difference in the mean mRSS change was observed between the glucocorticoid-supplemented group and the control group (P = 0.64).
- Secondary outcomes, including progressive fibrosis and scleroderma renal crisis, also showed no significant between-group differences.
Conclusions:
- Adding low-dose oral glucocorticoids to standard immunosuppression does not provide significant benefit for skin fibrosis in early dcSSc.
- The studied dosage of glucocorticoids did not elevate the risk of scleroderma renal crisis, indicating a favorable safety profile in this regard.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
222
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
222
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117